TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3343-4
Abstract: PurposeThis phase I trial evaluated the safety, pharmacokinetic profile, and antitumor activity of investigational oral TORC1/2 inhibitor TAK-228 plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.MethodsSixty-seven patients received TAK-228 6–40 mg via three dosing… read more here.
Keywords: plus paclitaxel; tak 228; trastuzumab patients; without trastuzumab ... See more keywords
107 Metabolic reprogramming to enhance the efficacy of mtor inhibition in colorectal cancer
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Investigative Medicine"
DOI: 10.1136/jim-2017-000663.107
Abstract: Purpose of study PI3K/mTOR pathway is mutated in 10%–20% of colorectal cancer (CRC) specimens and has been associated with poor survival. In this study, we found diacylglycerol kinase (DGK), involved in lipid signalling, to be… read more here.
Keywords: dgk; mtor inhibition; tak 228; inhibition ... See more keywords
Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-3498
Abstract: Purpose: The purpose of this study was to evaluate the rational combination of TORC1/2 inhibitor TAK-228 and Aurora A kinase inhibitor alisertib in preclinical models of triple-negative breast cancer (TNBC) and to conduct a phase… read more here.
Keywords: alisertib; combination; tak 228; solid tumors ... See more keywords
Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer-ANETT.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.584
Abstract: 584 Background: Neoadjuvant endocrine therapy is standard care for women with hormone receptor-positive breast cancer. However, both primary and acquired endocrine resistance is not uncommon, thereby limiting efficacy. [1] The PI3K-Akt-mTOR pathway is a major… read more here.
Keywords: breast cancer; receptor positive; tak 228; receptor ... See more keywords
Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.3017
Abstract: 3017 Background: Sapanisertib (TAK-228) is a potent, selective ATP-competitive, dual inhibitor of mTORC1/2. Metformin is thought to inhibit the mTOR pathway through upstream activation of AMPK suggesting combination therapy may enhance anti-tumor activity of TAK-228.… read more here.
Keywords: combination; tak 228; metformin; combination metformin ... See more keywords
The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13112778
Abstract: Simple Summary Hyperactivation of the PI3K/AKT/mTOR cell signalling pathway is an important and well-described mechanism of trastuzumab resistance in HER2-positive breast cancer. In cell-line models of acquired trastuzumab resistance generated in our laboratory, we demonstrate… read more here.
Keywords: her2 positive; tak 228; positive breast; breast cancer ... See more keywords